Business
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine comp
About this update from Lexeo Therapeutics, Inc.
[{"type":"image","alt":"Lexeo Therapeutics","displaySize":"","headline":null,"caption":"Lexeo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNNLd9kZ10lMRyd7r.aoKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/12a596ea7105503183002156834260ac","width":300,"height":116}},"lazy":false},{"type":"text","content":"Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures","length":180,"tagName":"p"},{"type":"text","content":"LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access ","length":200,"tagName":"p"},{"type":"text","content":"NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the U.S. Food and Drug administration (FDA) has granted Breakthrough Therapy designation to LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich ataxia (FA). LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, intended to enable earlier patient access to therapies with expedited clinical development timelines.","length":671,"tagName":"p"},{"type":"text","content":"“Receiving Breakthrough Therapy designation is a significant milestone, highlighting the potential of LX2006 and the strength of clinical evidence generated to date,” said Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics. “We are highly encouraged by the impact of LX2006 on key measures of cardiac health, especially given the lack of treatments for FA cardiomyopathy today, which is the leading cause of death in FA. We are also optimistic about the improvements we have observed in functional measures of FA more broadly, and we look forward to a continued partnership with the FDA through the Breakth...